EGFR and non-small cell lung carcinoma: Indeed, several histone deacetylate inhibitors (HDACi), including entinostat and trichostatin A, have been shown to restore expression of CDH1 and promote sensitivity to EGFR TKIs in pre-clinical models of EGFR-mutant NSCLC (Sharma et al., 2010; Suda et al., 2011; Weng et al., 2018).